Ellaella

[Ellaella @ellaellaeeh2017]

@curlingisgreat @jonesrrrrrr Did u read?

[Ellaella @ellaellaeeh2017]

@BioTechCash Face mogged 😂

[Ellaella @ellaellaeeh2017]

@Ceazar_Black Are you an insider?

[Ellaella @ellaellaeeh2017]

@Jim_Rothman Im bullish on $ALLR but this is BS. Please dont start this AMC shit. Stop lying to people.

[Ellaella @ellaellaeeh2017]

@KLunsj Alsooo fake news

[Ellaella @ellaellaeeh2017]

@KLunsj Great, feel free to also sell if u want then shhh 😊

[Ellaella @ellaellaeeh2017]

@kaizen000000000 Sky daddy

[Ellaella @ellaellaeeh2017]

@parti_king Got mogged

[Ellaella @ellaellaeeh2017]

@kanu1483076 This is my exact question! Im bullish on $ALLR but damn, ppl need to tone shit down

[Ellaella @ellaellaeeh2017]

@Anatolydaily Does he know Ronnie Coleman?

[Ellaella @ellaellaeeh2017]

@benjjjj4 Its a big achievement imho

[Ellaella @ellaellaeeh2017]

$ALLR A Notice of Allowance is a formal message from the patent office saying: your patent application has been reviewed and is approved for issuance, assuming the applicant completes the final required steps, usually paying the issue fee and filing any final paperwork.

[WTec @WTec78]

$ALLR @AllarityTx Announce Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office https://t.co/ZuquvDdDr5

[Ellaella @ellaellaeeh2017]

@little_kitsuneh @TiloJung This is so fire

[Ellaella @ellaellaeeh2017]

@jerryPopsGerald Hahah that was not the point

[Ellaella @ellaellaeeh2017]

Beware the pump. $ALLR is promising, but CRC is still early. Preclinical data isn’t proven patient benefit. Be bullish if you want; just don’t confuse hype with facts.

[Ellaella @ellaellaeeh2017]

@Moneymanrupert No need to lead with insults. Yes it is undervalued but 5b or 10b right now? I’ve seen some bombastic numbers and others claiming outrageous claims about shorts (same as we saw with AMC). It’s too early for that.

[Ellaella @ellaellaeeh2017]

@Ceazar_Black Are your revenue numbers based on gross list price or realistic net sales after rebates, discontinuations, and real-world attrition?
And why apply a 3–5x peak sales acquisition multiple to a preclinical CRC program as if it’s already a de-risked commercial asset?

[Ellaella @ellaellaeeh2017]

@Ceazar_Black Isn’t citing two long-duration ovarian patients a weak basis for assuming CRC responders will have similar average duration, given they’re different tumors and different treatment settings?

[Ellaella @ellaellaeeh2017]

@Ceazar_Black Why are you using 18–30 months average time on drug in CRC when approved refractory mCRC drugs typically show treatment durations measured in months, not years?

[Ellaella @ellaellaeeh2017]

@Ceazar_Black How are you getting from ~159,000 total new U.S. CRC cases to 25,000–50,000 new treated later-line patients per year for ALLR, when stenoparib’s CRC data are still preclinical and not even human efficacy data yet?